JP2014525474A - 光過敏性てんかんの予防または治療における使用のための１ｈ−キナゾリン−２，４−ジオンの使用 - Google Patents

光過敏性てんかんの予防または治療における使用のための１ｈ−キナゾリン−２，４−ジオンの使用 Download PDF

Info

Publication number
JP2014525474A
JP2014525474A JP2014529647A JP2014529647A JP2014525474A JP 2014525474 A JP2014525474 A JP 2014525474A JP 2014529647 A JP2014529647 A JP 2014529647A JP 2014529647 A JP2014529647 A JP 2014529647A JP 2014525474 A JP2014525474 A JP 2014525474A
Authority
JP
Japan
Prior art keywords
dioxo
dihydro
quinazolin
methanesulfonamide
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014529647A
Other languages
English (en)
Japanese (ja)
Inventor
クーチャー，クラウス
ジョンズ，ドナルド
アンベール，ジョージ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2014525474A publication Critical patent/JP2014525474A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014529647A 2011-09-07 2011-09-07 光過敏性てんかんの予防または治療における使用のための１ｈ−キナゾリン−２，４−ジオンの使用 Withdrawn JP2014525474A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/050687 WO2013036224A1 (en) 2011-09-07 2011-09-07 Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy

Publications (1)

Publication Number Publication Date
JP2014525474A true JP2014525474A (ja) 2014-09-29

Family

ID=44652020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014529647A Withdrawn JP2014525474A (ja) 2011-09-07 2011-09-07 光過敏性てんかんの予防または治療における使用のための１ｈ−キナゾリン−２，４−ジオンの使用

Country Status (10)

Country Link
EP (1) EP2753331A1 (enExample)
JP (1) JP2014525474A (enExample)
KR (1) KR20140071405A (enExample)
CN (1) CN103889427A (enExample)
AU (1) AU2011376333A1 (enExample)
BR (1) BR112014005210A2 (enExample)
CA (1) CA2846503A1 (enExample)
IN (1) IN2014DN01791A (enExample)
MX (1) MX2014002693A (enExample)
WO (1) WO2013036224A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
AU2016381366A1 (en) 2015-12-30 2018-06-28 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
CN1870999A (zh) 2003-10-31 2006-11-29 阿斯利康(瑞典)有限公司 炔烃ⅰ
EP1677788A1 (en) 2003-10-31 2006-07-12 AstraZeneca AB Alkynes iii
CA2549969A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes ii
WO2005079802A1 (en) 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
KR20080076962A (ko) 2005-12-20 2008-08-20 노파르티스 아게 대사성 글루타메이트 수용체 조절제로서의 니코틴산 유도체
ES2753141T3 (es) * 2009-11-03 2020-04-07 Lupin Ltd Formulación de liberación modificada de lacosamida

Also Published As

Publication number Publication date
KR20140071405A (ko) 2014-06-11
IN2014DN01791A (enExample) 2015-05-15
WO2013036224A1 (en) 2013-03-14
AU2011376333A1 (en) 2014-03-13
EP2753331A1 (en) 2014-07-16
MX2014002693A (es) 2014-06-04
BR112014005210A2 (pt) 2017-03-21
CN103889427A (zh) 2014-06-25
CA2846503A1 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
DE602004007225T2 (de) Methode zur behandlung von erkrankungen der unteren harnwege
US10111889B2 (en) Uses of ganaxolone
JP2003510273A (ja) 神経障害性の疼痛の治療のためのレチガビンの使用
EA017443B1 (ru) Производные тетрагидрохинолина для лечения посттравматических стрессовых расстройств
US20140163050A1 (en) Use of 1H-quinazoline-2,4-diones
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
ES2936833T3 (es) Tasimelteón para tratar síndrome de Smith-Magenis
US20040266737A1 (en) Compounds of use in the treatment of epilepsy, seizure, and electroconvulsive disorders
JP2003520193A (ja) Ｒ（−）−ケトプロフェンを用いる神経障害性疼痛、耳鳴り、およびその他の障害治療のための方法および組成物
EP3258930A1 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
US20220273662A1 (en) Use of sildenafil and rock inhibitors for treating stroke or sequelae following stroke
JP2014525474A (ja) 光過敏性てんかんの予防または治療における使用のための１ｈ−キナゾリン−２，４−ジオンの使用
EA023728B1 (ru) Терапевтическое средство от тревожных расстройств
KR20180101322A (ko) 뇌졸중으로부터의 회복을 위한 방법 및 조성물
JP2019516699A (ja) 純粋な５−ｈｔ６受容体アンタゴニストとアセチルコリンエステラーゼ阻害剤の組合せ
JP6629464B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種類の組合せ
JP6606298B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニストのｎｍｄａ受容体アンタゴニストとの組合せ
Herrling et al. D-CPPene (SDZ EAA-494)—a competitive NMDA antagonist: pharmacology and results in humans
CA2814828A1 (en) Method of treatment for mental disorders
KR20200132858A (ko) 간질 치료제
KR102336701B1 (ko) 실데나필 및 rock 저해제를 포함하는 뇌졸중으로 인한 인지 기능 저하의 치료용 약학적 조성물
JP5830983B2 (ja) 抗癌剤の副作用軽減剤
WO2021224235A1 (en) Use of dopamine d3 partial agonists for treating central nervous system disorders
BR112021004938A2 (pt) métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3
JP2012533605A (ja) 神経セロイドリポフスチン症の治療における使用のための１ｈ−キナゾリン−２，４−ジオン

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20141202